Trials / Completed
CompletedNCT04779892
The Study of Infliximab (CMAB008 and Remicade) in Healthy Subjects to Compare the PK and Safety
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
A phase 1, Randomized, Double-blind, Parallel group, Sing-dose study to compare the Pharmacokinetics and Safety of CMAB008 and Remicade in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Infliximab | 100mg/vial |
Timeline
- Start date
- 2020-02-01
- Primary completion
- 2020-06-15
- Completion
- 2020-06-15
- First posted
- 2021-03-03
- Last updated
- 2021-10-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04779892. Inclusion in this directory is not an endorsement.